COMMUNIQUÉS West-GlobeNewswire

BioCorRx Reports Business Update for the Second Quarter of 2024
15/08/2024
ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business [...]
Orion Corporation: Managers’ transactions – Hao Pan
15/08/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 15 AUGUST 2024 at 15.30 EEST Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596 [...]
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
15/08/2024
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE [...]
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor
15/08/2024
CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Pathos AI, Inc. ( www.pathos.com ), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform [...]
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15/08/2024
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel [...]
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
15/08/2024
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and schedule Overall survival, the strongest result from the Phase 2 trial, will be the primary study endpoint Agreed-upon early [...]
Empower: Discover the Future of Healthcare at Inovalon’s Annual Data-Driven Summit
15/08/2024
Hear from Former CDC Director and Visionary Executives from AWS, Oracle Cloud Infrastructure, Snowflake, and Many Other Organizations on the Forefront of Data-Driven Healthcare BOWIE, Md., Aug. 15, 2024 (GLOBE NEWSWIRE [...]
Noah Medical Shares Diagnostic Confidence of its Galaxy Users at AABIP 2024
15/08/2024
Next-generation robotics company to share field results, deliver interactive simulations and host multiple events for its Galaxy System at leading bronchology and pulmonology gathering SAN CARLOS, Calif., Aug. 15, 2024 [...]
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15/08/2024
Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipeline Appointment [...]
Lifeward Reports Second Quarter 2024 Financial Results
15/08/2024
Record ReWalk revenue with 20 systems placed Q2’24 revenue of $6.7M up over 400% compared to $1.3M in Q2’23 Medicare claims for submissions from prior quarters beginning to be paid MARLBOROUGH, Mass. and YOKNEAM ILLIT, [...]
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15/08/2024
ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment [...]
Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform
15/08/2024
CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]
SciSparc Updates Regarding the Status of the AutoMax Merger
14/08/2024
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its shareholders to approve [...]
Yield10 Bioscience Announces Second Quarter 2024 Financial Results
14/08/2024
WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended [...]
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
14/08/2024
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
14/08/2024
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release [...]
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
14/08/2024
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results [...]
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
14/08/2024
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today [...]
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
14/08/2024
Company to host conference call on August 15, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]

Pages